Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLM101 in PMM2-CDG (POLAR Trial)
NCT06892288Phase 3Active, not recruiting
- Sponsor
- Glycomine
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in phosphomannomutase 2 deficiency (PMM2-CDG) comparing GLM101 with Placebo -> GLM101 (2 arms). Primary endpoint: International Cooperative Ataxia Rating Scale at 24 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 deficiency (PMM2-CDG)
Beyond the preview
Go deeper on NCT06892288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892288.